Bnb Plus's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Bnb Plus (BNBX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Bnb Plus vs Its Competitors
- TTM: Trailing 12-month revenue of 2M vs 16,784M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+1.1% annualized vs trailing 12 months), vs accelerating (+3.6%) for its tracked peer group.
- Growth: Bnb Plus generated 98.9% revenue growth year over year in Q3 2026, vs 5.8% for its tracked competitors combined.
- Profitability: Its -773.1% net margin compares with 5.5% for the peer group.
- Scale: Bnb Plus ranks #63 of 71 companies by market capitalization in the IT Infrastructure industry, holding 0.0% of industry market cap.
- Peer revenue share: Bnb Plus accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.18M compares with $0.47M for the peer group (0.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BNBX Sales vs. its Competitors, Q3 2026
Bnb Plus reported revenue growth of 98.86 % year on year in Q3 2026, above its competitors' combined revenue growth of 5.78 %.
With a net margin of -773.09 %, Bnb Plus reported lower profitability than its competitors (5.52 %).
Bnb Plus generated 0.01 % of the combined sales of its peer group, up from 0.01 % a year earlier.
Bnb Plus vs. its Competitors, Q3 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Bnb Plus and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Bnb Plus Corp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (7) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (4) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Bnb Plus's competitor groups requires a Commercial License.
For context: the IT Infrastructure industry grew revenue 21.0% year over year, combined, vs 98.9% for Bnb Plus. Bnb Plus's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Bnb Plus's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Bnb Plus Corp | No | No | No | No |
| Competitors combined (10) | ||||
| High-Confidence Competitors (10) | ||||
| Similar-Size Competitors (7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BNBX Stock Performance relative to its Competitors
BNBX Stock Performance relative to High-Confidence Competitors
BNBX Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ieh Corp | 282.9% | Outperformed |
| 2 | Precigen Inc | 282.9% | Outperformed |
| 3 | Charles River Laboratories International inc | 282.9% | Outperformed |
| 4 | Quest Diagnostics Inc | 282.9% | Outperformed |
| 5 | Novartis Ag | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Bnb Plus's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Bnb Plus's Comment on Competition and Industry Peers
Publicly Traded Peers of Bnb Plus Corp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Bnb Plus Corp | 1.17 | 2.39 |
| Novartis Ag | 287,150.40 | 56,674.00 |
| Quest Diagnostics Inc | 26,613.44 | 11,560.00 |
| Charles River Laboratories International inc | 14,146.51 | 3,998.99 |
| Precigen Inc | 2,767.01 | 31.60 |
| Fulgent Genetics Inc | 626.19 | 322.97 |
| SUBTOTAL | 332,052.32 | 73,506.80 |
Sign in to see all competitors of Bnb Plus Corp .
Sources: Bnb Plus Corp's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Bnb Plus Corp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Bnb Plus's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Precigen, Inc. | Named by the company | 85% |
| Novartis AG | Named by the company | 85% |
| MaxCyte, Inc. | Named by the company | 85% |
| Syngoi Technologies, S.L.U. | Named by the company | 85% |
| Blue Heron Biotech, LLC | Named by the company | 85% |
| GenScript Biotech Corporation | Named by the company | 85% |
| Solana Company | Named by the company | 85% |
| ANSA Biotechnologies | Named by the company | 85% |
| Forward Industries, Inc. | Named by the company | 85% |
| Merck & Co., Inc. | Named by the company | 85% |
| Quantoom Bioscience | Named by the company | 85% |
| The Ether Machine | Named by the company | 85% |
| 4basebio PLC | Named by the company | 85% |
| CEA Industries, Inc. | Named by the company | 85% |
| Integrated DNA Technologies, Inc. | Named by the company | 85% |
| OriGene Technologies, Inc. | Named by the company | 85% |
| Strategy, Inc. | Named by the company | 85% |
| Bitmine Immersion Technologies Inc. | Named by the company | 85% |
| Gene Art | Named by the company | 85% |
| MilliporeSigma | Named by the company | 85% |
| Sharplink Gaming Inc | Named by the company | 85% |
| Touchlight Genetics Ltd. | Named by the company | 85% |
| Aldevron, LLC | Named by the company | 85% |
| Elegen, Inc. | Named by the company | 85% |
| Quest Diagnostics Inc | Named by the company | 85% |
| Generation Bio Co | Named by the company | 85% |
| Charles River Laboratories International inc | Named by the company | 85% |
| Collectors Universe Inc | Named by the company | 85% |
| Ieh Corp | Named by the company | 85% |
| Digimarc Corp | Named by the company | 85% |
| Fulgent Genetics Inc | Named by the company | 85% |
| Myriad Genetics Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Bnb Plus's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Bnb Plus's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Bnb Plus Corp | Therapeutic DNA Production 62.34 % |
| Quest Diagnostics Inc | Diagnostic Information Services Business 97.86 % |
| Charles River Laboratories International inc | Discovery and Safety Assessment 59.94 % |
| Precigen Inc | Reportable 100.00 % |
| Fulgent Genetics Inc | Precision Diagnostics 57.08 % |
| Maxcyte inc | Cell Engineering Technology Segment 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Bnb Plus's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Bnb Plus Corp | 1 | 184,172 | -2,709,438 |
| Novartis Ag | 287,150 | 752,973 | 185,566 |
| Quest Diagnostics Inc | 26,613 | 202,807 | 19,526 |
| Charles River Laboratories International inc | 14,147 | 202,994 | -11,995 |
| Precigen Inc | 2,767 | 197,469 | -1,277,613 |
| Fulgent Genetics Inc | 626 | 240,307 | -63,593 |
| PEERS TOTAL | 332,051 | 469,188 | 91,352 |
Bnb Plus's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Charles River Laboratories International inc | United States 54.61 % |
| Fulgent Genetics Inc | Other countries 4.93 % |
| Maxcyte inc | US 68.55 % |
| Digimarc Corp | Non Us 75.35 % |
| Ieh Corp | US 94.77 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Bnb Plus's Position in Industry Market Structure
Market-capitalization share and concentration across all 66 companies in Bnb Plus's industry classification, broader than the peer set above. Market cap in millions of $.Bnb Plus ranks #63 of 66 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,231, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amphenol Corporation | 217,810 | 24.51 % |
| 2 | Danaher Corporation | 158,640 | 17.85 % |
| 3 | Vertiv Holdings Co | 97,926 | 11.02 % |
| 4 | Keysight Technologies inc | 62,400 | 7.02 % |
| 5 | Teradyne Inc | 1,234 | 5.2% |
| 6 | Ametek Inc | 1,234 | 5.2% |
| 7 | Roper Technologies Inc | 1,234 | 5.2% |
| 8 | Hubbell Inc | 1,234 | 5.2% |
| 9 | Veralto Corporation | 1,234 | 5.2% |
| 10 | Mks Inc | 1,234 | 5.2% |
| 63 | Bnb Plus Corp | 1 | 0.00 % |
Market cap and industry share for the rest of Bnb Plus's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-25.
Bnb Plus's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 58 | Quarta rad Inc | 6 | - |
| 59 | Phaos Technology cayman Holdings Ltd | 4 | - |
| 60 | Ostin Technology Group Co Ltd | 4 | - |
| 61 | Cemtrex Inc | 1,234 | 12.3% |
| 62 | Focus Universal Inc | 1,234 | 12.3% |
| 63 | Bnb Plus Corp | 1 | -95.29 % |
| 64 | Nuvve Holding Corp | 1,234 | 12.3% |
| 65 | Scantech Ai Systems Inc | 1,234 | 12.3% |
| 66 | Video Display Corporation | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Bnb Plus's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Bnb Plus's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the IT Infrastructure industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (79 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 59.36 % | 39.24 % (avg) | +20.1 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | -1,215.15 % | 5.24 % (avg) | -1,220.4 pp |
| Capital Intensity (Capex / Revenue) | - | 3.72 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Bnb Plus's Valuation vs Competitive Position
Valuation multiples vs the IT Infrastructure industry average (79 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 39.9x | - |
| EV / EBITDA | - | 20.9x | - |
| P/B | 0.5x | 4.7x | -4.2x |
| Return on Equity | -553.19 % | industry aggregate | -566.84 % |
| Return on Invested Capital | - | -0.81 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Bnb Plus's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -7.92 % | 24.11 % | -43.29 % | 297.28 % | 66.41 % | -57.64 % | -60.20 % | -38.22 % |
| Operating Margin | -281.83 % | -166.19 % | -442.56 % | -127.61 % | -54.79 % | -165.69 % | -397.30 % | - |
| Return on Invested Capital | -181.52 % | -194.76 % | -82.82 % | -54.96 % | -47.21 % | -74.68 % | -75.04 % | - |
| P/E | - | - | - | - | - | - | 0.3x | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Bnb Plus's BCG Growth-Share Matrix
Relative market share (vs Bnb Plus's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Bnb Plus falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.6% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Bnb Plus's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,231 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Bnb Plus's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Bnb Plus's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Bnb Plus's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Bnb Plus falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Bnb Plus's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 566.8 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Bnb Plus's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Bnb Plus Corp | 1.10 | 1.72 | - |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Quest Diagnostics Inc | 0.22 | 1.22 | 0.76 |
| Charles River Laboratories International inc | 0.18 | 1.34 | 0.78 |
| Precigen Inc | 0.58 | 3.60 | 6.05 |
| Fulgent Genetics Inc | 0.68 | 6.24 | 0.00 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Bnb Plus's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Bnb Plus Corp | Q2 2026 | +98.9 % | - |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Quest Diagnostics Inc | Q2 2026 | +10.2 % | +12.8 % |
| Charles River Laboratories International inc | Q2 2026 | -2.7 % | - |
| Precigen Inc | Q1 2026 | +1,633.9 % | - |
| Fulgent Genetics Inc | Q2 2026 | +4.9 % | - |
| PEERS TOTAL | +9.3 % | +19.8 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Bnb Plus's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Bnb Plus Corp | Q2 2026 | -47.1 % | - |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Quest Diagnostics Inc | Q2 2026 | +10.9 % | +27.8 % |
| Charles River Laboratories International inc | Q2 2026 | - | -11.9 % |
| Precigen Inc | Q1 2026 | +132.6 % | -58.5 % |
| Fulgent Genetics Inc | Q2 2026 | +27.0 % | -43.5 % |
Bnb Plus's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Bnb Plus Corp | - | - | - |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Quest Diagnostics Inc | 6.74% | 8.05% | 14.85% |
| Charles River Laboratories International inc | - | - | - |
| Precigen Inc | - | - | - |
| Fulgent Genetics Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Bnb Plus's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Bnb Plus Corp | - | 0.49 |
| Novartis Ag | 20.53 | 5.07 |
| Quest Diagnostics Inc | 25.17 | 2.30 |
| Charles River Laboratories International inc | - | 3.54 |
| Precigen Inc | - | 87.58 |
| Fulgent Genetics Inc | - | 1.94 |
| PEERS AVERAGE | 23.26 | 4.52 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.